The Biden administration’s handling of a petition for the government to “march in” on the patents of the prostate cancer drug Xtandi will likely set a precedent for whether the government is willing to use march-in rights under the Bayh-Dole Act to lower prices for drugs developed with taxpayer funding, according to 62 consumer groups in support of the petition . Xtandi was developed with funding from the U.S. Army and the National Institutes of Health, and it costs three...